Drugs / rgp120/HIV-1 SF-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000946 | ? → Mar 2001 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rgp120/HIV-1 SF-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000946 ↗ |
| Known as | HIV-1 SF-2 rgp120 | “The HIV-1 SF-2 p24 and HIV-1 SF-2 rgp120 vaccines are mixed with an adjuvant, which is a substance that increases immune response.” NCT00000946 ↗ |
| Modality | Vaccine | “The HIV-1 SF-2 p24 and HIV-1 SF-2 rgp120 vaccines are mixed with an adjuvant, which is a substance that increases immune response.” NCT00000946 ↗ |